ChiCTR2600121802 版本V1.0 版本创建时间2026/04/03 09:08:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121802 

最近更新日期:

Date of Last Refreshed on:

2026-04-03 09:08:03 

注册时间:

Date of Registration:

2026-04-03 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

超声引导与体表标志法用于女性甲状腺手术患者颈浅丛阻滞的效果对比

Public title:

The effect of ultrasound guidance and body surface marker in women patients with thyroid surgery was compared

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导与体表标志法用于女性甲状腺手术患者颈浅丛阻滞的效果对比

Scientific title:

The effect of ultrasound guidance and body surface marker in women patients with thyroid surgery was compared

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李姝颖 

研究负责人:

刘海涛 

Applicant:

Li Shuying 

Study leader:

Liu Haitao 

申请注册联系人电话:

Applicant telephone:

+86 177 3697 6049

研究负责人电话:

Study leader's telephone:

+86 151 3011 9853

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1261573209@qq.com

研究负责人电子邮件:

Study leader's E-mail:

mzlht@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

石家庄市新华区和平西路215号

研究负责人通讯地址:

石家庄市新华区和平西路215号

Applicant address:

No. 215 Heping West Road, Xinhua District, Shijiazhuang City

Study leader's address:

No. 215 Heping West Road, Xinhua District, Shijiazhuang City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第二医院

Applicant's institution:

The Second Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第二医院

Affiliation of the Leader:

The Second Hospital of Hebei Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-R580

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第二医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of the second hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-25 00:00:00

伦理委员会联系人:

安雯婷

Contact Name of the ethic committee:

An Wenting

伦理委员会联系地址:

石家庄市新华区和平西路215号

Contact Address of the ethic committee:

No. 215 Heping West Road, Xinhua District, Shijiazhuang City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 136 4321 6430

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第二医院

Primary sponsor:

The Second Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

石家庄市新华区和平西路215号

Primary sponsor's address:

No. 215 Heping West Road, Xinhua District, Shijiazhuang City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北医科大学第二医院

具体地址:

石家庄市新华区和平西路215号

Institution
hospital:

The Second Hospital of Hebei Medical University

Address:

No. 215 Heping West Road, Xinhua District, Shijiazhuang City

经费或物资来源:

研究生课题

Source(s) of funding:

postgraduate project

Target disease:

postoperation pain

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

通过对比超声引导下颈浅丛神经阻滞技术与体表标志法颈浅丛神经阻滞技术在女性甲状腺手术患者中的应用,观察其阻滞效果、神经阻滞相关并发症及对术中、术后镇痛药物用量的影响,为提高患者舒适度和快速康复提供临床参考。  

Objectives of Study:

By comparing the application of ultrasound-guided superficial cervical plexus nerve block technique and surface landmark-based superficial cervical plexus nerve block technique in female patients undergoing thyroid surgery, the block effect, nerve block-related complications and the impact on the dosage of intraoperative and postoperative analgesic drugs were observed to provide clinical references for improving patient comfort and rapid recovery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.美国麻醉医师协会(ASA)分级Ⅰ-Ⅱ级; 2.年龄在18岁以上的女性患者; 3.择期行甲状腺切除术的患者; 4.麻醉方式为全麻联合颈浅丛神经阻滞麻醉; 5.患者及授权委托人同意参加本研究,并签署知情同意书。

Inclusion criteria

1. American Society of Anesthesiologists (ASA) classification grade I - II; 2. Female patients over 18 years old; 3. Patients undergoing elective thyroidectomy; 4. Anesthesia method is general anesthesia combined with superficial cervical plexus nerve block anesthesia; 5. Patients and authorized representatives agree to participate in this study and sign the informed consent form.

排除标准:

1.对麻醉用药( 如各类全麻及局麻药等) 过敏者; 2.凝血功能障碍患者; 3.穿刺部位存在感染、解剖畸形或肿瘤侵犯者; 4.存在非甾体抗炎药(NSAIDs)禁忌症者(如活动性消化道溃疡、严重肾功能不全、阿司匹林哮喘等); 5.术前存在严重神经系统疾病或认知功能障碍,影响沟通及疼痛评估者; 6.拒绝加入本研究者。

Exclusion criteria:

1. Patients allergic to anesthetic drugs (such as various general anesthetics and local anesthetics, etc.); 2. Patients with coagulation disorders; 3. Patients with infection, anatomical deformity or tumor invasion at the puncture site; 4. Patients with contraindications to non-steroidal anti-inflammatory drugs (NSAIDs) (such as active peptic ulcer, severe renal insufficiency, aspirin-induced asthma, etc.); 5. Patients with severe neurological diseases or cognitive dysfunction before surgery, which affect communication and pain assessment; 6. Patients who refuse to participate in this study.

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2026-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-17 00:00:00 To 2026-03-31 00:00:00  

干预措施:

Interventions:

组别:

L组:接受体表标志法双侧颈浅丛神经阻滞。

样本量:

50

Group:

Group L: received superficial cervical plexus block by receiving body surface marker.

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

U组:接受超声引导下双侧颈浅丛神经阻滞。

样本量:

50

Group:

Group U: bilateral superficial cervical plexus block under ultrasound guidance.

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北省 

市(区县):

 

Country:

China 

Province:

Hebei  

City:

 

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后疼痛视觉模拟量表评分

指标类型:

主要指标

Outcome:

Postoperative Pain Visual Analogue Scale Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后阿片类药物用量

指标类型:

次要指标

Outcome:

Postoperative Opioid Dosage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首次需要镇痛药物时间

指标类型:

次要指标

Outcome:

The first time when painkillers are needed

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中阿片类药物用量

指标类型:

次要指标

Outcome:

The amount of opioid drugs used during the operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度评分

指标类型:

次要指标

Outcome:

Patient satisfaction score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将在研究结束后通过Figshare平台共享,访问需提交申请并获伦理委员会批准。数据为去标识化的CSV格式,仅供非商业研究使用,共享期限为5年。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be shared via the Figshare platform at the end of the study, and access is subject to an application and approval by the Ethics Committee. The data is in a de-identified CSV format for non-commercial research use only and is shared for a period of 5 years.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF),电子采集和管理系统(Electronic Data Capture, EDC),

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-03 09:08:03